Literature DB >> 32205973

Radical Gastrectomy: Still the Gold Standard Treatment for Gastric Cancer-Our Experience from a Tertiary Care Center from Northeast India.

Joydeep Purkayastha1, Jitin Yadav1, Abhijit Talukdar1, Gaurav Das1, Niju Pegu1, Srishti Madhav2, Pritesh R Singh1, Vinay Mamidala1.   

Abstract

Gastric cancer (GC) is common in the northeast and southern parts of India. Radical surgery is the cornerstone of treatment and offers the only chance for cure. This study was conducted to assess the outcomes of all resectable gastric cancers that presented to our tertiary cancer center in Northeast India. All patients undergoing upfront surgery for gastric cancer with curative intention between 2012 and 2017 were included in the study. A total of 116 patients who underwent upfront radical gastrectomy were included in the study. Males (58.6%) were more common than females (41.4%). Mean age at presentation was 56.12 years (range 26-89). The most common mode of presentation was pain abdomen (53.8%). The most common location of tumor was the distal part (81%) followed by the proximal part (10.3%). The most commonly done procedure was distal radical gastrectomy (56.9%) followed by subtotal gastrectomy (32.8%). Median number of lymph nodes isolated was 14. Fifty-four patients received adjuvant chemotherapy while 32 patients received adjuvant chemoradiation (CTRT). At a median follow-up of 14 months (range, 2-78 months), overall 5-year survival was 23.75% (mean survival 33.77 months, median survival 24 months). The 5-year survival for stages I-III was 100%, 26.25%, and 11.25%, respectively (P < 0.001). Though perioperative chemotherapy has a role in gastric cancer, it is not the substitute for radical D2 gastrectomy which is still the gold standard treatment especially in high-volume centers. © Indian Association of Surgical Oncology 2019.

Entities:  

Keywords:  ACCORD 07 trial; D2 lymph node dissection; Gastrectomy; MAGIC trial; Perioperative chemotherapy

Year:  2019        PMID: 32205973      PMCID: PMC7064675          DOI: 10.1007/s13193-019-00990-x

Source DB:  PubMed          Journal:  Indian J Surg Oncol        ISSN: 0975-7651


  15 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

Review 2.  Adjuvant and neoadjuvant therapy of gastric cancer: a comparison of three pivotal studies.

Authors:  Takeshi Sano
Journal:  Curr Oncol Rep       Date:  2008-05       Impact factor: 5.075

3.  Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial.

Authors:  Marc Ychou; Valérie Boige; Jean-Pierre Pignon; Thierry Conroy; Olivier Bouché; Gilles Lebreton; Muriel Ducourtieux; Laurent Bedenne; Jean-Michel Fabre; Bernard Saint-Aubert; Jean Genève; Philippe Lasser; Philippe Rougier
Journal:  J Clin Oncol       Date:  2011-03-28       Impact factor: 44.544

4.  D2 lymphadenectomy for gastric cancer in Tata Memorial Hospital: Indian data can now be incorporated in future international trials.

Authors:  Shailesh V Shrikhande; Parul J Shukla; Sajid Qureshi; Ravichand Siddachari; Vivek Upasani; Mukta Ramadwar; Anagha C Kakade; Rohini Hawaldar
Journal:  Dig Surg       Date:  2006-07-12       Impact factor: 2.588

5.  [D2 lymph node dissection in gastric cancer surgery: long term results--analysis of an experience with 227 patients].

Authors:  C Vasilescu; V Herlea; S Tidor; B Ivanov; Oana Stănciulea; M Mănuc; C Gheorghe; M Ionescu; M Diculescu; I Popescu
Journal:  Chirurgia (Bucur)       Date:  2006 Jul-Aug

6.  Extended lymph-node dissection for gastric cancer.

Authors:  J J Bonenkamp; J Hermans; M Sasako; C J van de Velde; K Welvaart; I Songun; S Meyer; J T Plukker; P Van Elk; H Obertop; D J Gouma; J J van Lanschot; C W Taat; P W de Graaf; M F von Meyenfeldt; H Tilanus
Journal:  N Engl J Med       Date:  1999-03-25       Impact factor: 91.245

7.  Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial.

Authors:  Ilfet Songun; Hein Putter; Elma Meershoek-Klein Kranenbarg; Mitsuru Sasako; Cornelis J H van de Velde
Journal:  Lancet Oncol       Date:  2010-04-19       Impact factor: 41.316

8.  Epidemiological review of gastric cancer in India.

Authors:  Rajesh P Dikshit; Garima Mathur; Sharayu Mhatre; B B Yeole
Journal:  Indian J Med Paediatr Oncol       Date:  2011-01

Review 9.  Failure to rescue patients from early critical complications of oesophagogastric cancer surgery.

Authors:  Elroy P Weledji; Vincent Verla
Journal:  Ann Med Surg (Lond)       Date:  2016-03-02

10.  D2 lymphadenectomy is not only safe but necessary in the era of neoadjuvant chemotherapy.

Authors:  Shailesh V Shrikhande; Savio G Barreto; Sanjay D Talole; Kumar Vinchurkar; Somashekar Annaiah; Kunal Suradkar; Shaesta Mehta; Mahesh Goel
Journal:  World J Surg Oncol       Date:  2013-02-02       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.